Related Experiment Video
Updated: Jul 4, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour--a case report
S van Wissen1, B A J Bastiaansen, A K Stroobants
1Department of Internal Medicine and Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. s.vanwissen@amc.uva.nl
Abstract:
The catastrophic antiphospholipid syndrome is characterised by rapid onset thromboses, often resistant to conventional anticoagulant treatment, and resulting in life threatening multiple organ dysfunction. The diagnosis of catastrophic antiphospholipid syndrome may be difficult, predominantly due to its frequently atypical presentation. We report a case of a 35-year-old female who presented with a pancreatic tumour and extensive thromboses. Following a storm of ischemic events due to thrombotic occlusions in spite of therapeutic heparin dose, the suspicion of catastrophic antiphospholipid syndrome emerged. The patient was successfully treated with anticoagulants, immunoglobulins, plasmapheresis and rituximab. The present report shows that the use of the diluted Russell's viper venom time can be helpful in providing additional information on the lupus anticoagulants antibody status, allowing careful monitoring of lupus anticoagulants conversion and hence response to therapy.
Related Concept Videos
Acute Pancreatitis II: Pathophysiology
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment: